Transgenic Mouse Model For Development Of Cancer Therapeutics
Background:
The National Cancer Institute's Medical Oncology Branch is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or
commercialize the thymidylate synthase transgenic mouse model.
Technology:
Thymidylate synthase (TS) is an enzyme that is essential for DNA
synthesis and repair. Elevated levels of TS protein and mRNA levels
are associated with many human cancers. NIH inventors have
demonstrated that ectopic expression of catalytically active TS
induces a transformed phenotype in mammalian cells manifested by
foci formation, anchorage independent growth, and tumor formation
in nude mice. Overexpression of human thymidylate synthase (hTS) in
murine islets provides a model to study genetic alterations
associated with the progression from normal cells to hyperplasia
and adenoma. This mouse model may be useful for cancer
prevention and the development of therapeutic strategies.
R&D Status: Thymidylate synthase
transgenic mice available under Material Transfer Agreement
IP Status: Research Tool.
Patent prosecution is not being pursued for this technology.
Value Proposition:
- Transgenic mouse model to develop cancer therapeutics
- Ability to conduct drug screening for tumor reduction and
prevention
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #787
Revised 12/04/2008